Oriana A Petruolo1, Melissa Pilewskie1, Sujata Patil2, Andrea V Barrio1, Michelle Stempel1, Hannah Y Wen3, Monica Morrow4. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. morrowm@mskcc.org.
Abstract
BACKGROUND: The benefit of neoadjuvant chemotherapy (NAC) in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancers and in invasive lobular carcinoma (ILC) is uncertain due to the low rates of pathologic complete response (pCR). OBJECTIVE: The aim of this study was to determine if pathologic features can identify subsets likely to benefit from NAC. METHODS: Patients with stage I-III ER+, HER2- breast cancer receiving NAC were retrospectively reviewed. Endpoints were downstaging to breast-conserving surgery (BCS) and nodal pCR after NAC. Patients were grouped by progesterone receptor (PR) status and grade/differentiation (high grade or poor [HP] vs. non-HP). RESULTS: From 2007 to 2016, 402 ER+/HER2- cancers in patients receiving NAC were identified. Median age was 50 years, 98% were clinical stage II-III, and 75% were cN+. Overall pCR rate was 5%; breast pCR in 7% and nodal pCR in 15% of cN+ patients (p < 0.0001). Patients with ILC initially ineligible for BCS (n = 56) were less likely to downstage than those with invasive ductal carcinoma (IDC; n = 183, 16 vs. 48%, p ≤ 0.0001), with a similar trend in the axilla (p = 0.086). The rates of BCS eligibility after NAC were highest in PR-/HP patients (62%) and lowest in PR+/non-HP patients (29%) [p = 0.005]. In the axilla, nodal pCR among cN+ patients (n = 301) ranged from 0 to 35% (p < 0.0001) within these groups, and was most frequent in PR-/HP patients. CONCLUSIONS: ER+/HER2- patients most likely to benefit from NAC are those with PR- and HP tumors. Patients with ILC are unlikely to downstage in the breast or axilla compared with IDC. The use of these criteria can assist in defining the initial treatment approach.
BACKGROUND: The benefit of neoadjuvant chemotherapy (NAC) in patients with estrogen receptor-positive (ER+)/humanepidermal growth factor receptor 2-negative (HER2-) breast cancers and in invasive lobular carcinoma (ILC) is uncertain due to the low rates of pathologic complete response (pCR). OBJECTIVE: The aim of this study was to determine if pathologic features can identify subsets likely to benefit from NAC. METHODS:Patients with stage I-III ER+, HER2- breast cancer receiving NAC were retrospectively reviewed. Endpoints were downstaging to breast-conserving surgery (BCS) and nodal pCR after NAC. Patients were grouped by progesterone receptor (PR) status and grade/differentiation (high grade or poor [HP] vs. non-HP). RESULTS: From 2007 to 2016, 402 ER+/HER2- cancers in patients receiving NAC were identified. Median age was 50 years, 98% were clinical stage II-III, and 75% were cN+. Overall pCR rate was 5%; breast pCR in 7% and nodal pCR in 15% of cN+ patients (p < 0.0001). Patients with ILC initially ineligible for BCS (n = 56) were less likely to downstage than those with invasive ductal carcinoma (IDC; n = 183, 16 vs. 48%, p ≤ 0.0001), with a similar trend in the axilla (p = 0.086). The rates of BCS eligibility after NAC were highest in PR-/HP patients (62%) and lowest in PR+/non-HP patients (29%) [p = 0.005]. In the axilla, nodal pCR among cN+ patients (n = 301) ranged from 0 to 35% (p < 0.0001) within these groups, and was most frequent in PR-/HP patients. CONCLUSIONS: ER+/HER2- patients most likely to benefit from NAC are those with PR- and HP tumors. Patients with ILC are unlikely to downstage in the breast or axilla compared with IDC. The use of these criteria can assist in defining the initial treatment approach.
Authors: Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: E H Lips; L Mulder; J J de Ronde; I A M Mandjes; A Vincent; M T F D Vrancken Peeters; P M Nederlof; J Wesseling; S Rodenhuis Journal: Breast Cancer Res Treat Date: 2011-04-07 Impact factor: 4.872
Authors: M E Straver; E J Th Rutgers; S Rodenhuis; S C Linn; C E Loo; J Wesseling; N S Russell; H S A Oldenburg; N Antonini; M T F D Vrancken Peeters Journal: Ann Surg Oncol Date: 2010-04-06 Impact factor: 5.344
Authors: C Criscitiello; G Curigliano; H J Burstein; S Wong; A Esposito; G Viale; M Giuliano; U Veronesi; M Santangelo; M Golshan Journal: Eur J Surg Oncol Date: 2016-10-29 Impact factor: 4.424
Authors: Johanna G H van Nes; Hein Putter; Jean-Pierre Julien; Michelle Tubiana-Hulin; Marc van de Vijver; Jan Bogaerts; Monika de Vos; Cornelis J H van de Velde Journal: Breast Cancer Res Treat Date: 2008-05-18 Impact factor: 4.872
Authors: Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt Journal: JAMA Date: 2013-10-09 Impact factor: 56.272
Authors: Abigail S Caudle; Tse-Kuan Yu; Susan L Tucker; Isabelle Bedrosian; Jennifer K Litton; Ana M Gonzalez-Angulo; Karen Hoffman; Funda Meric-Bernstam; Kelly K Hunt; Thomas A Buchholz; Elizabeth A Mittendorf Journal: Breast Cancer Res Date: 2012-05-23 Impact factor: 6.466
Authors: W Truin; G Vugts; R M H Roumen; A J G Maaskant-Braat; G A P Nieuwenhuijzen; M van der Heiden-van der Loo; V C G Tjan-Heijnen; A C Voogd Journal: Ann Surg Oncol Date: 2015-05-16 Impact factor: 5.344
Authors: Nina Tamirisa; Hannah V Williamson; Samantha M Thomas; Kelly E Westbrook; Rachel A Greenup; Jennifer K Plichta; Laura H Rosenberger; Terry Hyslop; Eun-Sil Shelley Hwang; Oluwadamilola M Fayanju Journal: J Surg Oncol Date: 2019-05-06 Impact factor: 3.454
Authors: Orli Friedman-Eldar; Tolga Ozmen; Salah James El Haddi; Neha Goel; Youley Tjendra; Susan B Kesmodel; Mecker G Moller; Dido Franceschi; Christina Layton; Eli Avisar Journal: Ann Surg Oncol Date: 2022-03-18 Impact factor: 5.344
Authors: M G Davey; É J Ryan; P J Folan; N O'Halloran; M R Boland; M K Barry; K J Sweeney; C M Malone; R J McLaughlin; M J Kerin; A J Lowery Journal: BJS Open Date: 2021-05-07